James Davis, MD
Nephrology · Saint Louis, MONPI 1518995299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations.
Across 79 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$164
- Amgen$159
- Boehringer Ingelheim$141
- OPKO Pharmaceuticals, LLC$135
- Travere Therapeutics, Inc.$119
- Novartis$107
- plus $689 from 16 others
Across 4 payments — averaging $17,020 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$45K
- Alnylam Pharmaceuticals Inc.$23K
What the payments were for
- Food & beverage$1,48598%
- Education$292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 8 | $164 |
| Amgen(2 entities) | 7 | $159 |
| Boehringer Ingelheim | 7 | $141 |
| OPKO Pharmaceuticals, LLC | 7 | $135 |
| Travere Therapeutics, Inc. | 11 | $119 |
| Novartis | 4 | $107 |
| Calliditas Therapeutics US Inc. | 5 | $102 |
| Mallinckrodt Hospital Products Inc. | 4 | $99 |
| AstraZeneca(2 entities) | 6 | $95 |
| Shield Therapeutics Inc | 4 | $73 |
| Merck | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Aurinia Pharma U.S., Inc. | 2 | $41 |
| Lilly USA, LLC | 1 | $28 |
| Fresenius USA Marketing, Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $24 |
| AbbVie | 1 | $23 |
| Novo Nordisk | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Akebia Therapeutics Inc | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
How this compares
$1,513 in reported general payments places this provider in the 65th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 42 | $43,073 |
| JardianceEmpagliflozin | 53 | $39,757 |
| OzempicSemaglutide | 13 | $12,200 |
| KerendiaFinerenone | 18 | $11,569 |
| Potassium Citrate ErPotassium Citrate | 26 | $2,208 |
| Clonidine | 17 | $1,685 |
| Bumetanide | 32 | $1,645 |
| Potassium Chloride | 50 | $811 |
| Nifedipine ErNifedipine | 53 | $792 |
| Losartan Potassium | 106 | $759 |
| Sodium Chloride0.9 % Sodium Chloride | 12 | $666 |
| Torsemide | 23 | $588 |
| Doxazosin Mesylate | 22 | $379 |
| Metoprolol Succinate | 36 | $349 |
| Valsartan | 13 | $343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $95 | $43,07342 claims |
| Boehringer IngelheimJardiance | $141 | $39,75753 claims |
| Novo NordiskOzempic | $19 | $12,20013 claims |
| BayerKerendia | $164 | $11,56918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 253 nephrology providers in Missouri.
Other nephrology in Saint Louis
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
- Tingting LiSaint Louis$130K
- Krista LentineSaint Louis$86K
- Rowena Delos SantosSaint Louis$30K
- Kabeya MwintshiSaint Louis$25K
- Naoka MurakamiSaint Louis$24K
- Benjamin HumphreysSaint Louis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.